RADA Schedules First Quarter 2017 Results Release & Conference Call on Wednesday, May 24, 2017
May 11, 2017 12:21 pm UTC| Business
NETANYA, Israel, May 11, 2017 -- RADA Electronic Industries Ltd. (Nasdaq:RADA) announced that it would be releasing its financial results for the first quarter of 2017 on Wednesday, May 24, 2017. The Company will host...
Endeavour Reaches Price Agreement to Increase its Ity Mine Ownership from 55% to 80%
May 11, 2017 12:10 pm UTC| Business
ENDEAVOUR REACHES PRICE AGREEMENT TO INCREASE ITS ITY MINE OWNERSHIP FROM 55% TO 80% View News Release in PDF Format Abidjan, May 11, 2017 - Endeavour Mining Corporation (TSX:EDV)(OTCQX:EDVMF) is pleased...
Banca IFIS S.p.A.: approved the results for the first 3 months of 2017
May 11, 2017 12:08 pm UTC| Business
Net banking income at 102,3 million Euro (+33,5%), profit for the period at 32,7 million Euro (+48,3%). Excellent credit quality of loans to SMEs. The CEO Giovanni Bossi: "Both the Interbanca integration and the...
May 11, 2017 12:05 pm UTC| Business
GAITHERSBURG, Md., May 11, 2017 -- Novavax, Inc. (Nasdaq:NVAX), today announced that Dr. James F. Cummings has been promoted to Vice President, Clinical Development and Translational Medicine. Dr. Cummings joined...
Obalon Receives Regulatory Approvals to Commercialize in Select Middle East Markets
May 11, 2017 12:03 pm UTC| Business
SAN DIEGO, May 11, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the...
Obalon Receives Regulatory Approvals to Commercialize in Select Middle East Markets
May 11, 2017 12:03 pm UTC| Business
SAN DIEGO, May 11, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the...
Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 11, 2017 12:02 pm UTC| Business
--Raised ~$20 million through an underwritten equity offering -- -- Factor IX Hemophilia B program milestone payment received after completion of IND-enabling toxicology studies -- -- Initiation of Hemophilia B Phase...